Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2482-2493

  Zhang, Xian ^a,b   He, Yantao ^a   Liu, Sijiu ^a   Yu, Zhihong ^a   Jiang, Zhong Xing ^a   Yang, Zhenyun ^a   Dong, Yuanshu ^a   Nabinger, Sarah C ^a   Wu, Li ^a   Gunawan, Andrea M ^a   Wang, Lina ^a   Chan, Rebecca J ^a   Zhang, Zhong Yin ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NANKAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE PHOSPHATASE SHP 2; PROTEIN TYROSINE PHOSPHATASE SHP 2 INHIBITOR; SALICYLIC ACID; UNCLASSIFIED DRUG;

ALPHA HELIX; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; COMBINATORIAL LIBRARY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG IDENTIFICATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; APOPTOSIS; AREA UNDER CURVE; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; MICE, INBRED C57BL; MICE, NUDE; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SALICYLIC ACID; SMALL MOLECULE LIBRARIES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949853380     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901645u     Document Type: Article

References (55)

1. Hunter, T. The Croonian lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. Philos. Trans. R. Soc. London, Ser. B 1998, 353, 583-605.
2. Tonks, N. K.; Neel, B. G. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr. Opin. Cell Biol. 2001, 13, 182-195.
3. Zhang, Z.-Y. Protein tyrosine phosphatases: prospects for therapeutics. Curr. Opin. Chem. Biol. 2001, 5, 416-423.
4. Ventura, J. J.; Nebreda, A. R. Protein kinases and phosphatases as therapeutic targets in cancer. Clin. Transi. Oncol. 2006, 5, 153-160.
5. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 2005, 353, 172-187.
6. Neel, B. G.; Gu, H.; Pao, L. The "Shp" ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 2003, 28, 284-293.
7. Chan, R. J.; Feng, G. S. PTPN11 is the first identified protooncogene that encodes a tyrosine phosphatase. Blood 2007, 109, 862-867.
8. Tiganis, T.; Bennett, A. M. Protein tyrosine phosphatase function: the substrate perspective. Biochem. J. 2007, 402, 1-15.
9. Tartaglia, M.; Mehler, E. L.; Goldberg, R.; Zampino, G.; Brunner, H. G.; Kremer, H.; van der Burgt, I.; Crosby, A. H.; Ion, A.; Jeffery, S.; Kalidas, K.; Patton, M. A.; Kucherlapati, R. S.; Gelb, B. D. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat. Genet. 2001, 29, 465-546
10. Tartaglia, M.; Gelb, B. D. Noonan syndrome and related disorders: genetics and pathogenesis. Annu. Rev. Genomics Hum. Genet. 2005, 5, 45-68.
11. Tartaglia, M.; Niemeyer, C. M.; Fragale, A.; Song, X.; Buechner, J.; Jung, A.; Hahlen, K.; Hasle, H.; Licht, J. D.; Gelb, B. D. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat. Genet. 2002, 34, 148-150.
12. Tartaglia, M.; Martinelli, S.; Cazzaniga, G.; Cordeddu, V.; Iavarone, I.; Spinelli, M.; Palmi, C.; Carta, C.; Pession, A.; Arico, M.; Masera, G.; Basso, G.; Sorcini, M.; Gelb, B. D.; Biondi, A. Genetic evidence for lineage-related and differentiation stagerelated contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004, 104, 307-313.
13. Loh, M. L.; Vattikuti, S.; Schubbert, S.; Reynolds, M. G.; Carlson, E.; Lieuw, K. H.; Cheng, J. W.; Lee, C. M.; Stokoe, D.; Bonifas, J. M.; Curtiss, N. P.; Gotlib, J.; Meshinchi, S.; Le Beau, M. M.; Emanuel, P. D.; Shannon, K. M. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004, 103, 2325-2331.
14. Loh, M. L.; Reynolds, M. G.; Vattikuti, S.; Gerbing, R. B.; Alonzo, T. A.; Carlson, E.; Cheng, J. W.; Lee, C. M.; Lange, B. J.; Meshinchi, S. Children's Cancer Group. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia 2004, 18, 1831-1834.
15. Kratz, C. P.; Niemeyer, C. M.; Castleberry, R. P.; Cetin, M.; Bergsträsser, E.; Emanuel, P. D.; Hasle, H.; Kardos, G.; Klein, C; Kojima, S.; Stary, J.; Trebo, M.; Zecca, M.; Gelb, B. D.; Tartaglia., M.; Loh., M. L. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/ myeloproliferative disease. Blood 2005, 106, 2183-2185.
16. Bentires-Alj, M.; Paez, J. G.; David, F. S.; Keilhack, H.; Halmos, B.; Naoki, K.; Maris, J. M.; Richardson, A.; Bardelli, A.; Sugarbaker, D. J.; Richards, W. G.; Du, J.; Girard, L.; Minna, J. D.; Loh, M. L.; Fisher, D. E.; Velculescu, V. E.; Vogelstein, B.; Meyerson, M.; Sellers, W. R.; Neel, B. G. Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res. 2004, 64, 8816-8820.
17. Chan, G.; Kalaitzidis, D.; Neel, B. G. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev. 2008, 27, 179-192.
18. Miyamoto, D.; Miyamoto, M.; Takahashi, A.; Yomogita, Y.; Higashi, H.; Kondo, S.; Hatakeyama, M. Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors. Oncogene 2008, 27, 3508-3515.
19. Hatakeyama, M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat. Rev. Cancer 2004, 4, 688-694.
20. Stommel, J. M.; Kimmelman, A. C.; Ying, H.; Nabioullin, R.; Ponugoti, A. H.; Wiedemeyer, R.; Stegh, A. H.; Bradner, J. E.; Ligon, K. L.; Brennan, C.; Chin, L.; DePinho, R. A. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318, 287-290.
21. Chen, L.; Sung, S.S.; Yip, M. L.; Lawrence, H. R.; Ren, Y.; Guida, W. C.; Sebti, S. M.; Lawrence, N. J.; Wu, J. Discovery of a novel shp2 protein tyrosine phosphatase inhibitor. Mol. Pharmacol. 2006, 70, 562-570.
22. Lawrence, H. R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S. S.; Szymanski, A. M.; Yip, M. L.; Guida, W. C.; Sebti, S. M.; Wu, J.; Lawrence, N. J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem. 2008, 51, 4948-4956.
23. Hellmuth, K.; Grosskopf, S.; Lum, C. T.; Würtele, M.; Röder, N.; von Kries, J. P.; Rosario, M.; Rademann, J.; Birchmeier, W. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 7275-7280.
24. Yu, W. M.; Guvench, O.; Mackerell, A. D.; Qu, C. K. Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay. J. Med. Chem. 2008, 51, 7396-7404.
25. Wu, D.; Pang, Y.; Ke, Y.; Yu, J.; He, Z.; Tautz, L.; Mustelin, T.; Ding, S.; Huang, Z.; Feng, G.-S. A conserved mechanism for control of human and mouse embryonic stem cell pluripotency and differentiation by shp2 tyrosine phosphatase. PLoS One 2009, 4,e4914.
26. Zhang, Z.-Y. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 209-234.
27. Puius, Y. A.; Zhao, Y.; Sullivan, M.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase IB: a paradigm for inhibitor design. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 13420-13425.
28. Zhang, S.; Zhang, Z.-Y. PTP1B as a drug target: recent development in PTP1B inhibitor discovery. Drug Discovery Today 2007, 12, 373-381.
29. Sarmiento, M.; Wu, L.; Keng, Y.-F.; Song, L.; Luo, Z.; Huang, Z.; Wu, G.-Z.; Yuan, A. K.; Zhang, Z.-Y. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase IB. J. Med. Chem. 2000, 43, 146-155.
30. Liang, F.; Huang, Z.; Lee, S.-Y.; Liang, J.; Ivanov, M. I.; Alonso, A.; Bliska, J. B.; Lawrence, D. S.; Mustelin, T.; Zhang, Z.-Y. Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague. J. Biol. Chem. 2003, 278, 41734-41741.
31. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem. Rev. 2003, 103, 893-930.
32. Gul, W.; Hamann, M. T. Indole alkaloid marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life Sci. 2005, 78 ,442-453.
33. Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem., Int. Ed. 2001, 40, 2004-2021.
34. Lewis, W. G.; Green, L. G.; Grynszpan, F.; Radić, Z.; Carlier, P. R.; Taylor, P.; Finn, M. G.; Sharpless, K. B. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem., Int. Ed. 2002, 41, 1053-1057.
35. Lee, L. V.; Mitchell, M. L.; Huang, S. J.; Fokin, V. V.; Sharpless, K. B.; Wong, C. H. A potent and highly selective inhibitor of human alpha-1,3-fucosyltransferase via click chemistry. J. Am. Chem. Soc. 2003, 125, 9588-9589.
36. Manetsch, R.; Krasiński, A.; Radić, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 2004, 126, 12809-12818.
37. Srinivasan, R.; Uttamchandani, M.; Yao, S. Q. Rapid assembly and in situ screening of bidentate inhibitors of protein tyrosine phosphatases. Org. Lett. 2006, 8, 713-716.
38. Xie, J.; Seto, C. T. A two stage click-based library of protein tyrosine phosphatase inhibitors. Bioorg. Med. Chem. 2007, 15, 458-473.
39. Yu, X.; Sun, J.-P.; He, Y.; Guo, X.-L.; Liu, S.; Zhou, B.; Hudmon, A.; Zhang, Z.-Y. Structure, inhibitor, and regulatory mechanism of Lyp, a lymphoid-specific tyrosine phosphatase implicated in autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 19767-19772.
40. Deb, T. B.; Wong, L.; Salomon, D. S.; Zhou, G.; Dixon, J. E.; Gutkind, J. S.; Thompson, S. A.; Johnson, G. R. A common requirement for the catalytic activity and both SH2 domains of SHP-2 in mitogen-activated protein (MAP) kinase activation by the ErbB family of receptors. A specific role for SHP-2 in map, but not c-Jun amino-terminal kinase activation. J. Biol. Chem. 1998, 273, 16643-16646.
41. Qu, C. K.; Yu, W. M.; Azzarelli, B.; Feng, G. S. Genetic evidence that Shp-2 tyrosine phosphatase is a signal enhancer of the epidermal growth factor receptor in mammals. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 8528-8533.
42. Maroun, C. R.; Naujokas, M. A.; Holgado-Madruga, M.; Wong, A. J.; Park, M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 2000, 20, 8513-8525.
43. Egan, S. E.; Giddings, B. W.; Brooks, M. W.; Buday, L.; Sizeland, A. M.; Weinberg, R. A. Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 1993, 363, 45-51.
44. Emanuel, P. D.; Bates, L. J.; Castleberry, R. P.; Gualtieri, R. J.; Zuckerman, K. S. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991, 77, 925-929.
45. Chan, R. J.; Leedy, M. B.; Munugalavadla, V.; Voorhorst, C. S.; Li, Y.; Yu, M.; Kapur, R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005, 105, 3737-3742.
46. Barr, A. J.; Ugochukwu, E.; Lee, W. H.; King, O. N.; Filippakopoulos, P.; Alfano, I.; Savitsky, P.; Burgess-Brown, N. A.; Muller, S.; Knapp, S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009, 136, 352-363.
47. Zhang, Z.-Y. Mechanistic studies on protein tyrosine phosphatases. Prog. Nucleic Acid Res. Mol. Biol. 2003, 73, 171-220.
48. Jia, Z.; Barford, D.; Flint, A. J.; Tonks, N. K. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase IB. Science 1995, 268, 1754-1758.
49. Sun, J.-P.; Fedorov, A. A.; Lee, S.-Y.; Guo, X.-L.; Shen, K.; Lawrence, D. S.; Almo, S. C.; Zhang, Z.-Y. Crystal structure of PTP1B in complex with a potent and selective bidentate inhibitor. J. Biol. Chem. 2003, 278, 12406-12414.
50. Yang, J.; Cheng, Z.; Niu, T.; Liang, X.; Zhao, Z. J.; Zhou, G. W. Structural basis for substrate specificity of protein-tyrosine phosphatase SHP-1. J. Biol. Chem. 2000, 275, 4066-4071.
51. Otwinowski, Z.; Minow, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
52. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 1994, 50, 157-163.
53. Brünger, A. T.; Adams, P.D.; Core, G. M.;DeLano, W.L.;Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 1998, 54, 905-921.
54. Brünger, A. T. The free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 1992, 355, 472-475.
55. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, G. J. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 1991, 47, 110-119.